Literature DB >> 1309849

Antibody-mediated neutralization of human papillomavirus type 11 (HPV-11) infection in the nude mouse: detection of HPV-11 mRNAs.

W Bonnez1, R C Rose, R C Reichman.   

Abstract

The nu/nu mouse xenograft is the only experimental system permitting the growth of human papillomaviruses (HPV). Previous studies demonstrating inhibition of HPV-11 infection by antibodies against HPV-11 virions have used indirect markers of infection, such as graft size and histopathologic features. The presence of HPV-11 mRNAs was used as a direct marker of infection: Infectious HPV-11 was incubated with rabbit serum raised against purified HPV-11 virions or with the corresponding preimmune serum (controls) before use in the mouse xenograft model, and HPV-11 mRNAs were detected by a method using reverse transcription and amplification by polymerase chain reaction. Graft size, histopathologic features, and the presence of capsid antigen were also assessed. Six weeks after infection, 1 of 23 grafts in the test group contained HPV-11 mRNAs compared with 19 of 20 controls (P less than .001). Therefore, antibody-mediated inhibition of infection by HPV-11 leads to blockade of genomic expression and is thus consistent with active prevention of viral penetration, that is, neutralization.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1309849     DOI: 10.1093/infdis/165.2.376

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Isolation and propagation of human papillomavirus type 16 in human xenografts implanted in the severe combined immunodeficiency mouse.

Authors:  W Bonnez; C DaRin; C Borkhuis; K de Mesy Jensen; R C Reichman; R C Rose
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

2.  Two E2 binding sites (E2BS) alone or one E2BS plus an A/T-rich region are minimal requirements for the replication of the human papillomavirus type 11 origin.

Authors:  J Z Lu; Y N Sun; R C Rose; W Bonnez; D J McCance
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

3.  Evaluation of temperature sensitivity of human papillomavirus type 11 by using the human xenograft severe combined immunodeficiency mouse model.

Authors:  W Bonnez; R C Rose; C Borkhuis; C Da Rin; R C Reichman
Journal:  J Clin Microbiol       Date:  1994-06       Impact factor: 5.948

Review 4.  How will HPV vaccines affect cervical cancer?

Authors:  Richard Roden; T-C Wu
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

5.  Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly.

Authors:  M Li; T P Cripe; P A Estes; M K Lyon; R C Rose; R L Garcea
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

6.  In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16.

Authors:  W I White; S D Wilson; W Bonnez; R C Rose; S Koenig; J A Suzich
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

7.  Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies.

Authors:  R C Rose; W I White; M Li; J A Suzich; C Lane; R L Garcea
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

8.  Oral immunogenicity of human papillomavirus-like particles expressed in potato.

Authors:  Heribert Warzecha; Hugh S Mason; Christopher Lane; Anders Tryggvesson; Edward Rybicki; Anna-Lise Williamson; John D Clements; Robert C Rose
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

9.  Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles.

Authors:  R C Rose; W Bonnez; R C Reichman; R L Garcea
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.